Request Demo
Last update 20 Mar 2025
Human normal immunoglobulin (Shenzhen Weiguang Biological )
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Immunoglobulin |
Synonyms- |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Jan 1993), |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Human normal immunoglobulin (Shenzhen Weiguang Biological )CTR20241512
评价静注人免疫球蛋白治疗原发免疫性血小板减少症（ITP）的有效性和安全性的开放、单臂、多中心Ⅲ期临床试验
[Translation] An open, single-arm, multicenter phase III clinical trial to evaluate the efficacy and safety of intravenous human immunoglobulin in the treatment of primary immune thrombocytopenia (ITP)
CTRI/2023/07/055259
A Prospective, Non-randomized, Open Label, Single Arm, Multicenter, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Human Normal Immunoglobulin for Intravenous Administration in Adult Patients with Chronic Primary Immune Thrombocytopenia. - NIL
100 Clinical Results associated with Human normal immunoglobulin (Shenzhen Weiguang Biological )
Login to view more data
100 Translational Medicine associated with Human normal immunoglobulin (Shenzhen Weiguang Biological )
Login to view more data
100 Patents (Medical) associated with Human normal immunoglobulin (Shenzhen Weiguang Biological )
Login to view more data
100 Deals associated with Human normal immunoglobulin (Shenzhen Weiguang Biological )
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Autoimmune Diseases | China | 01 Jan 1994 | |
| Primary Immunodeficiency Diseases | China | 01 Jan 1994 | |
| Secondary immunodeficiencies | China | 01 Jan 1994 | |
| Measles | China | 01 Jan 1993 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Purpura, Thrombocytopenic, Idiopathic | Phase 3 | China | 24 Jun 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free